311 related articles for article (PubMed ID: 8607240)
1. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy.
Coetzee LJ; Hars V; Paulson DF
Urology; 1996 Feb; 47(2):232-5. PubMed ID: 8607240
[TBL] [Abstract][Full Text] [Related]
2. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
3. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
[TBL] [Abstract][Full Text] [Related]
4. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
6. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
[TBL] [Abstract][Full Text] [Related]
7. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
8. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant and salvage radiotherapy after radical prostatectomy.
Höcht S; Wiegel T; Schostak M; Hinkelbein W
Onkologie; 2002 Jun; 25(3):201-6. PubMed ID: 12119453
[TBL] [Abstract][Full Text] [Related]
10. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer.
Valicenti RK; Chervoneva I; Gomella LG
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249
[TBL] [Abstract][Full Text] [Related]
11. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
12. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
13. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen levels after radical prostatectomy and immediate adjuvant hormonal treatment for stage D1 prostate cancer are predictive of early disease outcome.
Cheng WS; Bergstralh EJ; Frydenberg M; Zincke H
Eur Urol; 1994; 25(3):189-93. PubMed ID: 7515348
[TBL] [Abstract][Full Text] [Related]
15. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
[TBL] [Abstract][Full Text] [Related]
16. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
17. Impact of Positive Surgical Margins after Radical Prostatectomy on Disease Progression and Adjuvant Treatment in Pathologically Localized Prostate Cancer.
Tomasković I; Milicić V; Tomić M; Ruzić B; Ulamec M
Coll Antropol; 2015 Sep; 39(3):697-700. PubMed ID: 26898068
[TBL] [Abstract][Full Text] [Related]
18. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
19. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer.
Valicenti RK; Gomella LG; Ismail M; Mulholland SG; Petersen RO; Corn BW
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):501-6. PubMed ID: 9806507
[TBL] [Abstract][Full Text] [Related]
20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
